{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-019877","form_type":"8-K","ticker":"ANEB","cik":"0001815974","company_name":"Anebulo Pharmaceuticals, Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.304736+00:00","generated_at":"2026-06-01T23:26:10.174103+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Anebulo Q3 FY2024 net loss $0.06/shr vs $0.11; pivots to pediatric cannabis antidote","bullets":["Net loss $1.7M ($0.06/shr), narrower than $2.8M ($0.11) a year ago; operating expenses $1.7M (down 41%).","Cash and equivalents $5.1M as of March 31, 2024, down from prior quarter but no near-term capital raise flagged.","Prioritizing IV formulation of selonabant for unintentional cannabis poisoning in children, citing growing medical need.","DEA plans to reclassify marijuana as Schedule III cited as tailwind; FDA discussions support alternative formulation for pediatric use.","Adult ACI treatment remains market opportunity but pediatric path seen as faster to approval; Phase 2 oral study data already completed."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-019877","json":"https://secwatch.observer/filing/0001493152-24-019877.json","markdown":"https://secwatch.observer/filing/0001493152-24-019877.md","text":"https://secwatch.observer/filing/0001493152-24-019877.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815974/000149315224019877/0001493152-24-019877-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815974/000149315224019877/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T23:26:10.174103+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"85ecc75b300a402e7b5d71d8bc96b284cc55bf32","claim":"Anebulo Pharmaceuticals, Inc. reported three months ended March 31, 2024 results: net income Net loss ... was $1.7 million, or $(0.06) per share, EPS $(0.06) per share.","evidence_excerpt":"today announced financial results for the three months ended March 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1815974/000149315224019877/0001493152-24-019877-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2024"},{"label":"Net income","value":"Net loss ... was $1.7 million, or $(0.06) per share"},{"label":"EPS","value":"$(0.06) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}